Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Wyeth
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects With Nonmalignant Pain Estudio abierto para evaluar la seguridad a largo plazo de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos en sujetos con dolor de origen no maligno
Primary: The primary objective of the study is to evaluate the long-term safety and tolerability of the subcutaneous formulation of MOA-728 in subjects with opioid-induced constipation who have nonmal...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP 2)/Calcium Phosphate Matrix (CPM) in Closed Diaphyseal Tibial Fractures
1. To demonstrate a reduction of time to fracture union based on assessments of radiographs by a central evaluation committee (CEC). 2. To demonstrate acceleration of return to normal function based o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Wyeth Pharmaceuticals Inc. - Global Medical Affairs
MAJ Il y a 4 ans
A Multicenter, Open-Label Study to Compare On-Demand Treatment With 2 Prophylaxis Regimens of Recombinant Coagulation Factor IX (BeneFIX) Reformulated Drug Product (rFIX-R) in subjects with Severe Hemophilia B
To evaluate the efficacy and safety of BeneFIX infused as prophylaxis regimens, compared with BeneFIX administered in an on-demand regimen only.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Global Medical Affairs
MAJ Il y a 4 ans
A Randomized Trial of Temsirolimus versus Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
To compare the safety and tolerability of temsirolimus and sorafenib when used as single agents in the second-line setting in subjects with advanced RCC who have failed prior first-line treatment with...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Wyeth Research Division
MAJ Il y a 4 ans
Phase II Study of SKI-606 in Subjects with Advanced or Metastatic Breast Cancer
Determine the rate of progression free survival (PFS) at 16 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Consumer Healthcare
MAJ Il y a 4 ans
TDS-943 MAXIMUM USE TOLERANCE STUDY
Safety - to assess application site reactions
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
MAJ Il y a 4 ans
A Double-Blind, Parallel, Randomized Extension Trial to Evaluate Safety and Efficacy of TMI-005 (Apratastat) in Subjects with Rheumatoid Arthritis on Methotrexate Who Have Completed Protocol 3140A1-200-WW
To determine the long-term safety of oral TMI-005 in subjects with RA who have been receiving MTX.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Pharmaceuticals B.V
MAJ Il y a 4 ans
PREVENTION OF THE PROGRESSION OF VERY EARLY SYMPTOMS INTO ANKYLOSING SPONDYLITIS: A PLACEBO CONTROLLED TRIAL WITH ETANERCEPT
Decrease of inflammation on MRI.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Wyeth, a Pfizer Company
MAJ Il y a 4 ans
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
To evaluate whether planned transition between 90 and 150 days post-transplantation to SRL-based therapy from TAC-based therapy is associated with a clinically relevant degree of improvement in renal ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research, Clinical Research and Development, Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 4 ans
A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC, CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASED GRANULES ADMINISTERED AS A SUSPENSION IN NEONATES AND PRETERM INFANTS WITH A CLINICAL DIAGNOSIS OF GASTROESOPHAGEAL REFLUX DISEASE
To determine whether or not consistent exposures can be achieved in neonates and preterm infants with presumed GERD receiving oral doses of pantoprazole
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant